117997-81-6

Usage

Chemical Properties

White powder

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 29456-09-5 L-glutamic acid γ-benzyl ester 

Downstream Products

• 118100-26-8 N^α-Boc-ε-benzyl-DL-glutamic acid dipentylamide 
• 7536-59-6 4-nitrophenyl γ-benzyl-N-tert-butoxycarbonylglutamate 
• 1221593-80-1 (S)-4-tert-butoxycarbonylamino-4-(4-cyano-benzylcarbamoyl)-butyric acid benzyl ester 
• 141-78-6 ethyl acetate 
• 947274-33-1 tert-butyl (2-oxo-1-phenylpiperidin-3-yl)carbamate 
• 99405-61-5 tert-butyl 2-(phenylcarbamoyl)pyrrolidine-1-carboxylate 
• 947274-34-2 C₂HF₃O₂*C₁₁H₁₄N₂O 
• 1259528-85-2 C₂HF₃O₂*C₁₁H₁₄N₂O 
• 1259536-25-8 N-(2-oxo-1-phenylpiperidin-3-yl)benzenesulfonamide 
• 1259536-37-2 N-benzyl-N-(2-oxo-1-phenylpiperidin-3-yl)-benzenesulfonamide 
• 1259536-39-4 benzyl 4-(tert-butoxycarbonylamino)-5-oxo-5-(N-(2-oxo-1-phenylpiperidin-3-yl)phenylsuIfonamido)pentanoate 
• 1446420-03-6 C₃₄H₃₅FN₈O₂S₃ 
• 1446420-04-7 C₃₄H₃₅FN₈O₃S₂ 
• 1446420-02-5 C₃₄H₃₅FN₈O₃S₂ 

Relevant academic research and scientific papers

Glutathione modified low molecular weight PEI for highly improved gene transfection ability and biocompatibility

The efficient delivery of therapeutic genes remains a major challenge in realizing a feasible gene-based treatment. Herein, a versatile oligopeptide, glutathione, was introduced to construct novel non-viral cationic gene vectors. Reduced/oxidized forms of

SYNTHESIS OF POLY(ETHYLENE GLYCOL) BLOCK COPOLYMERS AS POTENTIAL WATER-SOLUBLE DRUG CARRIERS

The synthesis of a model water-soluble drug carrier based on poly(ethylene glycol) (PEG) block copolymers is described.In the copolymers, two blocks of PEG are linked by a biodegradable oligopeptide or amino acid linkage containing the glutamic acid residue. 4-Nitroaniline as a drug model is attached to the γ-carboxyl group of glutamic acid of the polymer carrier via an enzymatically degradable oligopeptide spacer.The oligopeptides used were potential substrates for chymotrypsin.The relationship between the structure of oligopeptides linking two PEG blocks and the rate of chymotrypsin-catalyzed polymer chain degradation as well as the relationship between the structure of the spacer and kinetics of drug model release from the carrier after incubation of chymotrypsin solution is discussed in detail.The results showed that by modifying the structure of oligopeptides in the polymer construct, changes in the rates of both polymer degradation and the drug model release can be achieved in a very broad range.